Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > This is great.

<< Previous

Bullboard Posts

Next >>

Post by stocksarefunon Nov 03, 2021 2:58pm

137 Views

Post# 34083425

This is great.

Are we at the point where we should try and broadcast this ticker across other networks beyond Stockhouse? Surprised we still have no mentions at all on Reddit in the last 200 days, and no stocktwits page.

Do the floodgates actually open when Phase 3 is announced? I have very little experience with phase 2 to phase 3 progression for biotechs in Canada.

How are you all feeling about this well kept secret?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market